MEDAVIE BLUE CROSS™

PRIOR AUTHORIZATION REQUEST

PROCEDURES FOR PRIOR AUTHORIZATION

Completed forms can be faxed in confidence to 1-514-286-8480 for residents of Quebec and 1-844-661-2640 for residents of all other provinces

Upon receipt, this request will be confidentially reviewed according to payment criteria developed by Medavie Blue Cross in consultation with independent health care consultants. In some cases, additional clinical or diagnostic information may be required to process your claim.

For Quebec residents, the criteria for prior authorization are adjusted to meet the requirements of the Régie de l'assurance maladie du Québec (RAMQ).

- Prior Authorization is a pre-approval process to determine if certain products will be reimbursed under a member's benefit plan.
- Please complete entire form. Incomplete forms cannot be processed.
- **For certain medications, approval for reimbursement may be conditional on confirmation of enrollment in the patient support program.**
- Prior Authorization may be limited to a specified period or quantity of medication.
  Some Medavie Blue Cross plans may require you to purchase a drug requiring prior authorization from a preferred pharmacy*. If your prior authorization request is approved, a case manager may contact you, your physician, or Patient Assistance Program to provide information about the program and to arrange to have your prescription transferred to the preferred pharmacy.
  **Not applicable in Quebec*.
- In cases where a request for Prior Authorization is declined, Medavie Blue Cross is denying payment for a product and is not challenging the medical opinion of the physician nor rendering a medical opinion.
- Any costs associated with the completion of this form or obtainment of additional medical information are the responsibility of the member.
- Renewal of the Prior Authorization will be considered by Medavie Blue Cross upon request from the patient/member. The renewal request should include information from the physician supporting continued use of the medication.
- Prior Authorization coverage is contingent on your continued status as a Medavie Blue Cross cardholder or beneficiary.
- If this is a request under the *Mesure du patient d'exception* for a Quebec resident, please include a completed *Patient d'exception* form that can be found here: www.medaviebc.ca/en/resources, in addition to this document.
- If you would like more information about our Patient First Network, including how your Patient Support Program can become integrated with our new enhanced Prior Authorization processes, please send an e-mail to: patientfirstnetwork@medavie.bluecross.ca.

Residents of All Other Provinces
PO BOX 220, MONCTON (NB) E1C 8L3
TEL.: 1-800-667-4511 FAX: 1-844-661-2640

Residents of Quebec
PO BOX 3300, STATION B, MONTREAL (QC) H3B 4Y5
TEL.: 1-888-588-1212 FAX: 1-514-286-8480

MEDAVIE BLUE CROSS™

PRIOR AUTHORIZATION REQUEST

1 PHARMACY INFORMATION

This section is to be completed by the Professional coordinating the request on behalf of the member (PSP, Cancer Care Navigator or Pharmacy)

Decision communication preference: ☐ Fax, Number: _____ ☐ Telephone, Number: _____

Name of Program/Pharmacy: _____

Contact Name: _____ Contact E-mail: _____

2 PATIENT INFORMATION

Part A

Patient Name: _____ Date of Birth: _____ (mm/dd/yyyy)

E-mail address of patient (or of legal guardian if patient is underage): _____

Address: _____ Suite: _____ City: _____

Province: _____ Postal Code: _____ Telephone Number: _____

Policy Number: _____ ID Number: _____

Do you have valid Medicare coverage in your current province of residence? ☐ Yes ☐ No

Have you already purchased this prescription? ☐ Yes ☐ No

Please attach your paid-in-full receipt with this request form. If you have already submitted your receipt to Medavie Blue Cross, please indicate the date of the oldest receipt. Date: _____ (mm/dd/yyyy)

Part B – Coordination of Benefits

Do you or any dependant have coverage for this drug under any other plan or program? ☐ Yes ☐ No **If Yes, complete the following:**

Policy Number: _____ Carrier: _____

(If applicable, please attach Explanation of Benefits from prior carrier with complete form)

If the patient is a dependent, provide the birth day and month of the cardholder for the other carrier: _____ (mm/dd)

Public-Funded Program – Have you applied for coverage through a public-funded program? ☐ Yes ☐ No

If No, please indicate why: _____

Part C – Authorization

I understand that the personal information I have provided herein is collected and used by Medavie Blue Cross to administer the terms of my policy or the group policy of which I am an eligible member, recommend suitable products and services that I am eligible for as a member of a policy, and other applicable purposes, as described in the Medavie Blue Cross Privacy Statement at **www.medaviebc.ca.**

Depending on the type of coverage I carry, limited personal information such as claim, health and/or financial related data may be collected from and/or released to following third parties as required for the purposes of administering and managing the benefits outlined in the policy of which I am an eligible member. These third parties may include healthcare providers, other insurance companies, regulatory authorities and investigative bodies, services providers, and/or the cardholder of any contract under which I am a participant.

Where allowed by law, my information may be shared with Medavie Blue Cross employees or service providers in jurisdictions other than where it was collected. If I am a resident of Quebec, this includes transferring or disclosing my personal information to Medavie Blue Cross employees or service providers outside of that province.

I understand that my consent is only valid for the time it is needed to achieve the purposes outlined herein, unless I withdraw it. I understand I may withdraw my consent at any time. However, in some instances doing so may prevent Medavie Blue Cross from providing me with certain products or services that may be useful to me and/or my dependents. This consent complies with federal and provincial privacy laws.

For more details about our information practices, including how your personal information is protected, how to access or correct personal information, or if you have concerns or questions, please see our Medavie Blue Cross Privacy Statement available at www.medaviebc.ca or call 1-800-667-4511.

Signature of Patient: **Date:** _____ (mm/dd/yyyy)

Residents of All Other Provinces
PO BOX 220, MONCTON (NB) E1C 8L3
TEL.: 1-800-667-4511 FAX: 1-844-661-2640

Residents of Quebec
PO BOX 3300, STATION B, MONTREAL (QC) H3B 4Y5
TEL.: 1-888-588-1212 FAX: 1-514-286-8480

3 SPECIALTY DRUG INFORMATION

Name of patient: _____ Date of Birth: _____

Policy Number: _____ ID Number: _____

E-mail address of patient or of legal guardian if patient is underage: _____

3A Patient Support Program (PSP) Enrollment

Is patient enrolled in the Patient Support Program? ☐ No ☐ Yes, specify Program ID #: _____

Indicate the name of the Patient Support Program: _____

PSP phone #: _____ PSP Fax #: _____

Product Name	Strength	Dosage	Diagnosis
NUCALA (MEPOLIZUMAB)			

Patient weight: _____ ☐ lbs ☐ kg Number of vials / syringes per dose: _____

Date treatment was initiated: _____ (mm/dd/yyyy) Expected duration of treatment: _____

Date of diagnosis: _____ (mm/dd/yyyy) Was treatment initiated in hospital? ☐ Yes ☐ No

Where is medication being administered? _____

Indicate the specialty of the physician who initiated or recommended the treatment: _____

Indicate if the disease or injury is work related: ☐ Yes ☐ No

For Initial Request, please complete sections 3B and 3D. For Renewals, please complete sections 3C and 3D.

3B Initial Request

Please list all the drugs that were previously tried, or could not be tried because of contraindications. The information for the following drug categories (relative to each diagnosis) must be provided, including details on the contraindication if applicable.

- **Hypereosinophilic syndrome: prednisone, hydroxyurea**
- **Severe eosinophilic asthma: inhaled corticosteroids, long-acting β2 agonists, leukotriene receptor antagonists, inhaled long-acting antimuscarinics, systemic corticosteroids**
- **Severe chronic rhinosinusitis with nasal polyps: intranasal corticosteroid therapy (Flonase, Nasacort, Rhinocort, Nasonex, Beconase, Avamys, Dymista, Omnaris, Ryaltris), systemic steroids**
- **Eosinophilic granulomatosis with polyangiitis: oral corticosteroids, prednisolone, cyclophosphamide, methotrexate, azathioprine, immunosuppressive therapy**

Category	Product Name	Dosage	Duration of Treatment	Response to Treatment or Contraindication

Is the drug being prescribed according to the Health Canada product monograph? ☐ Yes ☐ No

*NOTE: Do not provide genetic test results.

Approved indications from Health Canada:

1. **Hypereosinophilic syndrome (HES)**

Blood eosinophil count: _____ eosinophils/μL

Number of exacerbations in the last 12 months: _____

Has the patient been diagnosed with F/P negative HES (non-myleoid) for at least 6 months? ☐ Yes ☐ No

Is the patient currently taking prednisone and unable to lower the dose? ☐ Yes ☐ No

↳ If yes, specify the dosage: _____ mg

3 SPECIALTY DRUG INFORMATION

Name of patient: _____ Date of Birth: _____

Policy Number: _____ ID Number: _____

E-mail address of patient or of legal guardian if patient is underage: _____

3B Initial Request (cont'd)

2. **Severe eosinophilic asthma**

Blood eosinophil count: _____ cells/µL **or** _____ x 10^9 / l

↳ ☐ at the time of initiation of the anti-IL-5 treatment

☐ in the 12 months preceding the anti-IL-5 treatment

☐ while on chronic (maintenance) oral corticosteroid therapy

Number of exacerbations in the last 12 months: _____

↳ Indicate whether the exacerbations required:

☐ systemic corticosteroids for at least 3 days

☐ an increase in the dose of a systemic corticosteroid in the case of patients receiving it on an ongoing basis

☐ an emergency department visit ☐ a hospitalization

Provide the result to at least one of the following questionnaires:

ACQ score: _____ ACT score: _____ SGRQ score: _____ AQLQ score: _____

☐ Patient is a smoker ☐ Patient is a non-smoker, specify for how many months: _____

3. **Severe chronic rhinosinusitis with nasal polyps (CRSwNP)**

Presence of bilateral nasal polyps: ☐ Yes ☐ No

Endoscopic nasal polyp score (NPS): Left nostril: _____ Right nostril: _____

Has the patient had symptoms for 12 weeks or more of chronic rhinosinusitis despite intranasal corticosteroid therapy? ☐ Yes ☐ No

Has the patient had sinonasal surgery? ☐ Yes ☐ No

Has the patient had a bilateral nasal endoscopy, anterior rhinoscopy, or computed tomography (CT)? ☐ Yes ☐ No

↳ If yes, indicate the result of the examination:

Presence of polyps reaching below the lower border of the middle turbinate or beyond in each nostril: ☐ Yes ☐ No

Meltzer clinical score: Left nostril: _____ Right nostril: _____

Other (specify) : _____

Presence of the following elements:

☐ Evidence of type 2 inflammation

Tissue eosinophil count: _____ per high-power field

Blood eosinophil count: _____ Total IgE: _____

☐ Asthma needing regular inhaled corticosteroids. ACQ score: _____

☐ SNOT-22 score: _____ ☐ Significant loss of smell

3 SPECIALTY DRUG INFORMATION

Name of patient: _____ Date of Birth: _____

Policy Number: _____ ID Number: _____

E-mail address of patient or of legal guardian if patient is underage: _____

3B Initial Request (cont'd)

4. **Eosinophilic granulomatosis with polyangiitis (EGPA)**

Indicate if there is history or presence of asthma plus eosinophilia: ☐ Yes ☐ No

Additional features of EGPA (select all that apply):

☐ A biopsy showing histopathological evidence of eosinophilic vasculitis, or perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation

☐ Anti-neutrophil cytoplasmic antibody (ANCA) positive (myeloperoxidase or proteinase)

☐ Neuropathy, mono or poly (motor deficit or nerve conduction abnormality)

☐ Alveolar hemorrhage (by bronchoalveolar lavage)

☐ Cardiomyopathy (established by echocardiography or Magnetic Resonance Imaging)

☐ Glomerulonephritis (hematuria, red cell casts, proteinuria)

☐ Sino-nasal abnormality

☐ Pulmonary infiltrates, non-fixed

☐ Palpable purpura

Does the disease threaten the patient's life or organs? ☐ Yes ☐ No

FFS score: _____

☐ The disease is relapsing:
- ☐ Increase in oral corticosteroids (OCS) dose
- ☐ Initiation/increased dose of immunosuppressive therapy
- ☐ Hospitalization within the past 2 years which occurred at least 12 weeks prior to treatment with mepolizumab whilst receiving prednisolone

☐ The disease is refractory:
- ☐ Failure to attain remission (BVAS=0) within the last 6 months following induction treatment with a standard regimen, administered for at least 3 months
- ☐ Recurrence of symptoms of EGPA whilst tapering OCS within 6 months of treatment

3C Renewal Request

Please provide information on the evolution of the disease to evaluate the response to treatment.

Date of initial evaluation (pretreatment): _____ (mm/dd/yyyy)

Date of most recent evaluation: _____ (mm/dd/yyyy)

1. **Hypereosinophilic syndrome (HES)**

	Result at the initial evaluation	Result at the most recent evaluation
Blood eosinophil count:	_____ cells/µL **or** _____ x 10^9 / l	_____ cells/µL **or** _____ x 10^9 / l
Daily dose of maintenance oral steroids:	Oral steroids: _____ Dose: _____ mg	Oral steroids: _____ Dose: _____ mg
Number of annual exacerbations as previously defined:	Number of exacerbations: _____ Exacerbations have required: _____	Number of exacerbations: _____ Exacerbations have required: _____

3 SPECIALTY DRUG INFORMATION

Name of patient: _____ Date of Birth: _____

Policy Number: _____ ID Number: _____

E-mail address of patient or of legal guardian if patient is underage: _____

3C Renewal Request (cont'd)

2. **Severe eosinophilic asthma**

	Result at the initial or previous evaluation	Result at the most recent evaluation
ACQ score:		
ACT score:		
SGRQ score:		
AQLQ score:		
Daily dose of maintenance oral steroids:	Oral steroids: _____ Dose: _____ mg	Oral steroids: _____ Dose: _____ mg
Number of asthma exacerbations requiring systemic corticosteroids for at least 3 days **or** emergency department visit **or** hospitalization:		

3. **Severe chronic rhinosinusitis with nasal polyps (CRSwNP)**

	Result at the initial or previous evaluation	Result at the most recent evaluation
Endoscopic nasal polyp score (NPS):	Left nostril: _____ Right nostril: _____	Left nostril: _____ Right nostril: _____
SNOT-22 score:		
Asthma symptoms (ACQ score):		
Meltzer clinical score:	Left nostril: _____ Right nostril: _____	Left nostril: _____ Right nostril: _____

Has there been an improvement or has improvement been maintained for the sense of smell? ☐ Yes ☐ No

Has there been an improvement or has improvement been maintained as shown in the reduced use of systemic steroids? ☐ Yes ☐ No

3 SPECIALTY DRUG INFORMATION

Name of patient: _____ Date of Birth: _____

Policy Number: _____ ID Number: _____

E-mail address of patient or of legal guardian if patient is underage: _____

3C Renewal Request (cont'd)

4. **Eosinophilic granulomatosis with polyangiitis (EGPA)**

Over a 52-week treatment period:

→ Remission achieved (BVAS = 0 and OCS dose ≤ 4 mg/day): ☐ Yes ☐ No

↳ If yes, indicate the duration of remission: _____ week(s)

→ ≥ 50% reduction in average OCS dose: ☐ Yes ☐ No

→ Number of relapses: _____

Number of relapses prior to mepolizumab therapy: _____

Has response to mepolizumab been maintained or improved since last renewal request? ☐ Yes ☐ No

3D Additional Information

Please indicate any additional information pertaining to this request.

MEDAVIE BLUE CROSS™

PRIOR AUTHORIZATION REQUEST

HEALTH PROFESSIONAL STATEMENT

I certify that I have reviewed all pages of this request and that all information provided is true, correct and complete.

First Name: _____ Last Name: _____ Permit Number: _____

Specialty: _____

Clinic Name: _____

Address: _____ Suite: _____

City: _____ Province: _____ Postal Code: _____

E-mail: _____ Telephone: _____ Fax: _____

Signature: Date: _____
(mm/dd/yyyy)

It is important to provide the requested information in detail to help avoid delay in assessing claims for the above drug. This form may be subject to audit.

Residents of All Other Provinces
PO BOX 220, MONCTON (NB) E1C 8L3
TEL.: 1-800-667-4511 FAX: 1-844-661-2640

Residents of Quebec
PO BOX 3300, STATION B, MONTREAL (QC) H3B 4Y5
TEL.: 1-888-588-1212 FAX: 1-514-286-8480